First United Bank & Trust Trims Position in Zoetis Inc. $ZTS

First United Bank & Trust lessened its position in shares of Zoetis Inc. (NYSE:ZTS) by 22.1% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,065 shares of the company’s stock after selling 870 shares during the quarter. First United Bank & Trust’s holdings in Zoetis were worth $478,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Portside Wealth Group LLC raised its stake in shares of Zoetis by 24.7% in the first quarter. Portside Wealth Group LLC now owns 33,709 shares of the company’s stock worth $5,550,000 after buying an additional 6,672 shares during the period. Tandem Investment Advisors Inc. raised its stake in Zoetis by 100.3% during the 1st quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company’s stock worth $65,140,000 after acquiring an additional 198,089 shares during the period. Soros Capital Management LLC boosted its position in shares of Zoetis by 32.0% in the first quarter. Soros Capital Management LLC now owns 17,441 shares of the company’s stock worth $2,872,000 after purchasing an additional 4,230 shares during the period. Flagship Harbor Advisors LLC increased its stake in Zoetis by 31.2% in the 1st quarter. Flagship Harbor Advisors LLC now owns 7,394 shares of the company’s stock worth $1,217,000 after buying an additional 1,760 shares in the last quarter. Finally, Horizon Financial Services LLC purchased a new position in Zoetis in the 1st quarter worth approximately $380,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Trading Down 0.4%

NYSE ZTS opened at $142.97 on Tuesday. Zoetis Inc. has a 52 week low of $139.34 and a 52 week high of $196.55. The company has a 50 day moving average price of $150.26 and a 200 day moving average price of $155.52. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The firm has a market cap of $63.36 billion, a PE ratio of 24.61, a price-to-earnings-growth ratio of 2.30 and a beta of 0.88.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. During the same quarter in the prior year, the business posted $1.56 EPS. The business’s revenue for the quarter was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Piper Sandler boosted their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Leerink Partners cut shares of Zoetis from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Leerink Partnrs lowered Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Argus reaffirmed a “buy” rating and issued a $190.00 target price on shares of Zoetis in a report on Tuesday, September 9th. Finally, Stifel Nicolaus lowered Zoetis from a “buy” rating to a “hold” rating and decreased their price target for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $200.88.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.